What is a stock summary page? Click here for an overview.
Business Description
Chunghwa Chemical Synthesis & Biotech Co Ltd
NAICS : 325412
SIC : 2834
ISIN : TW0001762003
Description
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | 3.09 | |||||
| Interest Coverage | 0.3 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.19 | |||||
| Beneish M-Score | -2.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.1 | |||||
| 3-Year EBITDA Growth Rate | -15.2 | |||||
| 3-Year EPS without NRI Growth Rate | -43.8 | |||||
| 3-Year Book Growth Rate | 5.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.67 | |||||
| 9-Day RSI | 56.87 | |||||
| 14-Day RSI | 51.09 | |||||
| 3-1 Month Momentum % | 5.87 | |||||
| 6-1 Month Momentum % | -14.15 | |||||
| 12-1 Month Momentum % | -26.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | |||||
| Quick Ratio | 1.11 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 437.27 | |||||
| Days Sales Outstanding | 64.76 | |||||
| Days Payable | 21.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.39 | |||||
| Dividend Payout Ratio | 1.19 | |||||
| 3-Year Dividend Growth Rate | -18.9 | |||||
| Forward Dividend Yield % | 2.39 | |||||
| 5-Year Yield-on-Cost % | 2.16 | |||||
| Shareholder Yield % | 0.83 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.27 | |||||
| Operating Margin % | 0.47 | |||||
| Net Margin % | 3.94 | |||||
| FCF Margin % | 26.94 | |||||
| ROE % | 1.58 | |||||
| ROA % | 1.06 | |||||
| ROIC % | 0.13 | |||||
| 3-Year ROIIC % | -58.76 | |||||
| ROC (Joel Greenblatt) % | 2.31 | |||||
| ROCE % | 1.81 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 50.3 | |||||
| Forward PE Ratio | 16.96 | |||||
| PE Ratio without NRI | 50.3 | |||||
| Shiller PE Ratio | 8.65 | |||||
| Price-to-Owner-Earnings | 8.87 | |||||
| PEG Ratio | 27.94 | |||||
| PS Ratio | 1.95 | |||||
| PB Ratio | 0.78 | |||||
| Price-to-Tangible-Book | 0.79 | |||||
| Price-to-Free-Cash-Flow | 7.27 | |||||
| Price-to-Operating-Cash-Flow | 5.63 | |||||
| EV-to-EBIT | 41.64 | |||||
| EV-to-EBITDA | 11.78 | |||||
| EV-to-Revenue | 2.43 | |||||
| EV-to-FCF | 8.8 | |||||
| Price-to-GF-Value | 0.89 | |||||
| Price-to-Projected-FCF | 0.92 | |||||
| Price-to-DCF (Earnings Based) | 1.96 | |||||
| Price-to-DCF (FCF Based) | 0.63 | |||||
| Price-to-Median-PS-Value | 0.87 | |||||
| Price-to-Graham-Number | 1.33 | |||||
| Price-to-Net-Current-Asset-Value | 73.8 | |||||
| Earnings Yield (Greenblatt) % | 2.4 | |||||
| FCF Yield % | 13.77 | |||||
| Forward Rate of Return (Yacktman) % | -5.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Chunghwa Chemical Synthesis & Biotech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,347.375 | ||
| EPS (TTM) (NT$) | 0.675 | ||
| Beta | 0.03 | ||
| 3-Year Sharpe Ratio | -0.39 | ||
| 3-Year Sortino Ratio | -0.55 | ||
| Volatility % | 23.4 | ||
| 14-Day RSI | 51.09 | ||
| 14-Day ATR (NT$) | 0.551091 | ||
| 20-Day SMA (NT$) | 33.9475 | ||
| 12-1 Month Momentum % | -26.48 | ||
| 52-Week Range (NT$) | 32.5 - 53.7 | ||
| Shares Outstanding (Mil) | 77.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chunghwa Chemical Synthesis & Biotech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chunghwa Chemical Synthesis & Biotech Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chunghwa Chemical Synthesis & Biotech Co Ltd Frequently Asked Questions
What is Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762)'s stock price today?
The current price of TPE:1762 is NT$33.95. The 52 week high of TPE:1762 is NT$53.70 and 52 week low is NT$32.50.
When is next earnings date of Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762)?
The next earnings date of Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762) is .
Does Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762) pay dividends? If so, how much?
The Dividend Yield % of Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762) is 2.39% (As of Today), Highest Dividend Payout Ratio of Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762) was 1.95. The lowest was 0.12. And the median was 0.33. The Forward Dividend Yield % of Chunghwa Chemical Synthesis & Biotech Co Ltd(TPE:1762) is 2.39%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers